Simultaneous Portal and Hepatic Vein Versus Portal Vein Embolizations for Hypertrophy of the Future Liver Remnant

Prior treatment

• Ongoing participation or participation within the 21 days prior to inclusion in the study in another therapeutic trial with an experimental drug
• Serious non-stabilized disease, active uncontrolled infection or other serious underlying disorder likely to prevent the patient from receiving the treatment
• Contraindication for the MRI : Pacemaker or neurosensorial stimulator or implantable defibrillator, cochlear implant, ferromagnetic foreign body similar to the nervous structure.
• Treatment with anticoagulants (heparin or AVK) that cannot be interrupted for 48 hours

Other illness

• Allergy or contra-indication to iodine contrast agents (thyrotoxicosis, allergy to the active substance or excipients)

Lab values

• Treatment with anti-platelets that cannot be interrupted for 5 days for aspirin or Plavix

Age

• Pregnancy (betaHCG positive), breast-feeding or the absence of effective contraception for women of child-bearing age

Other

• Patient with cirrhosis
• Presence of clinical ascites
• Legal incapacity (persons in custody or under guardianship)
• Deprived of liberty Subject (by judicial or administrative decision)
• Impossibility to sign the informed consent document or to adhere to the medical follow-up of the trial for geographical, social or psychological reasons

• Liver metastases from colo-rectal origin considered as resectable (as validated by a multidisciplinary committee with at least one senior hepatic surgeon) provided sufficient FRL volume
• Percentage of FRL volume \< 30%
• Age ≥ 18 years
• General health status World Health Organisation 0,1
• Estimated life expectancy \> 3 months
• Patients whose biological parameters are :
  • Platelets ≥100,000/mm3,
  • Polynuclear neutrophils ≥ 1000/mm3,
  • Hemoglobin≥ 9g/dL (even transfused patients can be included)
  • Creatininemia \< 1.5 times the normal value
  • Creatinine clearance \> 30 milliliters (mL)/min
  • Bilirubinemia ≤ 1,5 times the normal value
  • liver transaminases ≤ 5 times the normal value
  • prothrombin rate \> 70%
• Reference liver CT-Scan or MRI done during the 30 days preceding PVE or LVD.
• Written informed consent
• National health insurance cover